Is the Weight Finally Over? Evaluation of Fixed-Dose versus Weight Based Dosing Strategies of 4-Factor Prothrombin Complex Concentrate

Newark, DE US
March 3, 2020

This presentation is intended to provide evidence based information to pharmacists and technicians at ChristianaCare regarding dosing strategies for 4-F PCC. Currently our institution doses 4-F PCC based on the FDA approved strategy of patient weight and INR. The goal is to present literature surrounding a fixed dose alternative strategy in order to assess the safety, efficacy, and cost outcomes. I plan to discuss the pathophysiology surrounding warfarin reversal, the pharmacology of 4-F PCC, other similar agents such as fresh frozen plasma and 3-F PCC, and how to apply both dosing strategies clinically. By the end of this presentation, the information presented will enable the pharmacists to assess how fixed dosing could potentially fit into our practice here at ChristianaCare.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Summarize the pharmacology of 4-F PCC
  2. State the differences between fixed dosing and weight based dosing 4-F PCC
  3. Describe the efficacy and safety of each dosing strategy
  4. Apply the literature to clinical scenarios in practice

Pharmacy technician learning objectives

  1. State the differences between fixed dosing and weight based dosing 4-F PCC
  2. Summarize the differences between 3-factor prothrombin complex concentrates, fresh frozen plasma, and 4-factor prothrombin complex concentrates

Additional Information

AttachmentSize
File Helpful Tips for Users.docx23.3 KB
File Information for CE Credit - Is the Weight Finally Over.docx122.93 KB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance
Course opens: 
03/03/2020
Course expires: 
04/16/2020
Event starts: 
03/03/2020 - 12:00pm CST
Event ends: 
03/03/2020 - 1:00pm CST
Cost:
$0.00
Add to calendar: 
ChristianaCare Hospital
4755 Ogletown-Stanton Rd.
Newark, DE 19713
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose
The presenter will discuss investigative use of drugs
 
Planning committee members
 
Katelyn McCormick, PharmD, BCPS
Emergency Medical Clinical Pharmacist
ChristianaCare Hospital
 
Ashley Weiner, PharmD
Pharmacy Resident
ChristianaCare Hospital
 
Course reviewer
 
Katrina K. Harper, PharmD, MBA, BCPS, BCSCP
Clinical Pharmacy Director, Sourcing Operations
Center for Pharmacy Practice Excellence
Vizient
 
Presenter
 
Ashley Weiner, PharmD
Pharmacy Resident
ChristianaCare Hospital
Joint Accreditation Statement:
 
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and ChristianaCare Hospital.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
___________________________________________
 
Designation Statements:
 
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-20-043-L01-P
Universal Activity Number: JA0006103-9999-20-043-L01-T
CEU
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU)

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance

Price

Cost:
$0.00
Please login or register to take this course.